<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01795313</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY19100001</org_study_id>
    <secondary_id>R01CA174858</secondary_id>
    <secondary_id>PRO12050422</secondary_id>
    <nct_id>NCT01795313</nct_id>
  </id_info>
  <brief_title>Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod</brief_title>
  <official_title>Immunotherapy for Recurrent Ependymomas in Children Using Human Leukocyte Antigen (HLA)-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ian F. Pollack, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Solving Kids' Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if vaccination with HLA-A2 restricted peptides, combined&#xD;
      with the immunoadjuvant imiquimod is safe and can induce immune responses in children with&#xD;
      recurrent ependymomas. Eligible patients are stratiﬁed by primary tumor location.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a pilot study to assess tolerability of our vaccine regimen in children with ependymomas initially arising above or below the tentorium</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with unacceptable toxicity</measure>
    <time_frame>2 years</time_frame>
    <description>Grade 3 or 4 non-hematological toxicities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor-associated antigen-specific T-cell</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Ependymoma</condition>
  <arm_group>
    <arm_group_label>HLA-A2 restricted tumor antigen vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single-arm study of a HLA-A2 restricted tumor antigen peptide vaccine, administered in conjunction with imiquimod</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HLA-A2 restricted synthetic tumor antigen</intervention_name>
    <arm_group_label>HLA-A2 restricted tumor antigen vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod</intervention_name>
    <arm_group_label>HLA-A2 restricted tumor antigen vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>enzyme-linked immunosorbent assay</intervention_name>
    <arm_group_label>HLA-A2 restricted tumor antigen vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <arm_group_label>HLA-A2 restricted tumor antigen vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <arm_group_label>HLA-A2 restricted tumor antigen vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>HLA-A2 restricted tumor antigen vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: All grades of ependymoma are eligible.&#xD;
&#xD;
          -  Patients must have recurrent/progressive ependymoma that has progressed or recurred&#xD;
             after initial adjuvant therapy.&#xD;
&#xD;
          -  HLA-A2 positive based on flow cytometry performed at the University of Pittsburgh.&#xD;
&#xD;
          -  Patients must have previously received standard initial therapy including attempted&#xD;
             gross total resection, where safely feasible, and in appropriate circumstances (e.g.,&#xD;
             those older than one year at initial diagnosis, with non-metastatic tumors and at&#xD;
             least microscopic residual disease), involved field fractionated radiation therapy&#xD;
             (RT). Patients may have received re-irradiation but not to the index lesion within 4&#xD;
             weeks.&#xD;
&#xD;
          -  Patients must be clinically stable and off or on low-dose (no more than 0.1 mg/kg/day,&#xD;
             max 4 mg/day Dexamethasone) corticosteroid for at least one week prior to study&#xD;
             registration.&#xD;
&#xD;
          -  Patients must be ≥ 12 months and &lt;22 years of age at the time of study registration.&#xD;
&#xD;
          -  Patients must have a performance status of ≥ 70; (Karnofsky if &gt; 16 years and Lansky&#xD;
             if ≤ 16 years of age).&#xD;
&#xD;
          -  Patients may have non-bulky, asymptomatic metastatic disease.&#xD;
&#xD;
          -  Males and females must agree to use effective birth control methods during the course&#xD;
             of vaccination (from the first vaccine to two weeks after the last vaccine).&#xD;
&#xD;
          -  Patients must be free of systemic infection requiring IV antibiotics at the time of&#xD;
             registration and off IV antibiotics for at least 7 days prior to registration.&#xD;
&#xD;
          -  Patients must have adequate organ function as measured by:&#xD;
&#xD;
               -  Bone marrow: Absolute neutrophil count (ANC) &gt; 1,000/µl; Platelets &gt; 100,000/µl&#xD;
                  (transfusion independent); Absolute lymphocyte count (ALC) ≥ 500/µl; Hemoglobin&#xD;
                  &gt;8 g/dl (may be transfused).&#xD;
&#xD;
               -  Hepatic: bilirubin ≤ 1.5x institutional normal for age; serum glutamate pyruvate&#xD;
                  transaminase (SGPT) &lt; 3x institutional normal&#xD;
&#xD;
               -  Renal: Serum creatinine based on age or creatinine clearance or radioisotope&#xD;
                  glomerular filtration rate (GFR) &gt; 70 ml/min/1.73 m²&#xD;
&#xD;
          -  Patients must have recovered from the toxic effects of prior therapy and be at least 3&#xD;
             weeks from the last dose of standard cytotoxic chemotherapy or myelosuppressive&#xD;
             biological therapy, at least one week from the last dose of non-myelosuppressive&#xD;
             biological therapy and at least 4 weeks from the completion of radiation therapy.&#xD;
&#xD;
          -  Patients must have no overt cardiac, gastrointestinal, pulmonary, or psychiatric&#xD;
             disease.&#xD;
&#xD;
        Patients must be willing to travel to Pittsburgh to receive the vaccine. Visits: Every 3&#xD;
        weeks x 9, then every 6 weeks x 12 depending on response/side effects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients living outside of North America are not eligible.&#xD;
&#xD;
          -  Patients must be off concurrent treatment or medications for at least 1 week&#xD;
             including: Interferon (e.g. Intron-A®), allergy desensitization injections, growth&#xD;
             factors (e.g. Procrit®, Aranesp®, Neulasta®), interleukins (e.g. Proleukin®), and any&#xD;
             investigational therapeutic medication.&#xD;
&#xD;
          -  Patients must not have a history of any immune system disorder or laboratory&#xD;
             abnormality or any condition that could potentially alter immune function.&#xD;
&#xD;
          -  Use of immunosuppressives within four weeks prior to study entry or anticipated use of&#xD;
             immunosuppressive agents. Patients must be on no more than 0.1 mg/kg/day, max 4 mg/day&#xD;
             dexamethasone for at least one week before study registration. Topical corticosteroids&#xD;
             are acceptable.&#xD;
&#xD;
          -  Patients with a known immune deficiency.&#xD;
&#xD;
          -  Pregnancy or breastfeeding. Female patients who are post-menarchal must have a&#xD;
             documented negative pregnancy test.&#xD;
&#xD;
          -  Tetanus vaccine during therapy or within 1 week prior to enrollment.&#xD;
&#xD;
          -  Patients who have received prior immunotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Broniscer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alberto Broniscer, MD</last_name>
    <phone>412-692-5055</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Dibridge</last_name>
      <phone>412-692-7070</phone>
      <email>sharon.dibridge@chp.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 12, 2013</study_first_submitted>
  <study_first_submitted_qc>February 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2013</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Ian F. Pollack, M.D.</investigator_full_name>
    <investigator_title>Professor of Neurosurgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ependymoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

